IMC-A12
(Cixutumumab)Phase 2Monoclonal antibody
Eli LillyCixutumumab is an experimental drug being studied to treat certain types of cancer, particularly those that grow when stimulated by a protein called IGF-1. It works by blocking this growth signal to slow or stop cancer cell growth.[1] IMC-A12 is currently being investigated across 22 indications[3], with its most advanced program in Phase 2.[1]
IMC-A12 is one of 527 biologic programs targeting Iris Melanoma. It is currently in Phase 2.
22
Indications
27
Total Trials
1
Active Trials
526
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 22 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1IMC-A12
Eli LillyPhase 2
Tecentriq
RochePreclinical
Trodelvy
GileadPreclinical
Halaven
EisaiPreclinical
Tykerb
GSKPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Prolia
AmgenPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer4 trials
Liver Cancer2 trials
Breast Cancer2 trials
Metastatic Prostate Cancer2 trials
15 more indications
Rhabdomyosarcoma1 trial
Recurrent or Refractory1 trial
Small Cell Lung Cancer1 trial
Refractory Solid Tumors1 trial
Pancreatic Cancer1 trial
Advanced Solid Malignancies1 trial
Primitive Neuroectodermal Tumor1 trial
Patients With Solid Tumors1 trial
Neuroendocrine Carcinoma1 trial
Metastatic Cancer1 trial
Metastatic Esophageal Adenocarcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cixutumumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]